Cargando…

Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness

AIMS: An epidemiological study carried out in 2006 indicated a high prevalence of blinding trachoma in the Kolofata Health District, Far North Region, Republic of Cameroon. As a result, the national blindness control programme of Cameroon instituted a trachoma elimination programme using the SAFE st...

Descripción completa

Detalles Bibliográficos
Autores principales: Huguet, P, Bella, L, Einterz, E M, Goldschmidt, P, Bensaid, P
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922718/
https://www.ncbi.nlm.nih.gov/pubmed/19692356
http://dx.doi.org/10.1136/bjo.2009.161513
_version_ 1782185454012989440
author Huguet, P
Bella, L
Einterz, E M
Goldschmidt, P
Bensaid, P
author_facet Huguet, P
Bella, L
Einterz, E M
Goldschmidt, P
Bensaid, P
author_sort Huguet, P
collection PubMed
description AIMS: An epidemiological study carried out in 2006 indicated a high prevalence of blinding trachoma in the Kolofata Health District, Far North Region, Republic of Cameroon. As a result, the national blindness control programme of Cameroon instituted a trachoma elimination programme using the SAFE strategy. METHODS: A campaign to treat the entire district population with azithromycin 1.5% eye drops was undertaken in February 2008. To measure the effectiveness of treatment on the prevalence of active trachoma, two epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the treatment campaign and the second study was performed 1 year later. RESULTS: The prevalence of active forms of trachoma (trachomatous inflammation—follicular (TF) + TF/trachomatous inflammation—intense (TI)) dropped from 31.5 (95% CI 26.4 to 37.5)% before treatment to 6.3 (95% CI 4.1 to 9.6)% 1 year after treatment—a reduction of nearly 80%. There were no reports of serious or systemic side effects. Tolerance was excellent and no treatment was interrupted. CONCLUSION: Mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated and effective.
format Text
id pubmed-2922718
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-29227182010-08-17 Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness Huguet, P Bella, L Einterz, E M Goldschmidt, P Bensaid, P Br J Ophthalmol Global Issues AIMS: An epidemiological study carried out in 2006 indicated a high prevalence of blinding trachoma in the Kolofata Health District, Far North Region, Republic of Cameroon. As a result, the national blindness control programme of Cameroon instituted a trachoma elimination programme using the SAFE strategy. METHODS: A campaign to treat the entire district population with azithromycin 1.5% eye drops was undertaken in February 2008. To measure the effectiveness of treatment on the prevalence of active trachoma, two epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the treatment campaign and the second study was performed 1 year later. RESULTS: The prevalence of active forms of trachoma (trachomatous inflammation—follicular (TF) + TF/trachomatous inflammation—intense (TI)) dropped from 31.5 (95% CI 26.4 to 37.5)% before treatment to 6.3 (95% CI 4.1 to 9.6)% 1 year after treatment—a reduction of nearly 80%. There were no reports of serious or systemic side effects. Tolerance was excellent and no treatment was interrupted. CONCLUSION: Mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated and effective. BMJ Group 2009-08-18 2010-02 /pmc/articles/PMC2922718/ /pubmed/19692356 http://dx.doi.org/10.1136/bjo.2009.161513 Text en © 2009, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Global Issues
Huguet, P
Bella, L
Einterz, E M
Goldschmidt, P
Bensaid, P
Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title_full Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title_fullStr Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title_full_unstemmed Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title_short Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
title_sort mass treatment of trachoma with azithromycin 1.5% eye drops in the republic of cameroon: feasibility, tolerance and effectiveness
topic Global Issues
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922718/
https://www.ncbi.nlm.nih.gov/pubmed/19692356
http://dx.doi.org/10.1136/bjo.2009.161513
work_keys_str_mv AT huguetp masstreatmentoftrachomawithazithromycin15eyedropsintherepublicofcameroonfeasibilitytoleranceandeffectiveness
AT bellal masstreatmentoftrachomawithazithromycin15eyedropsintherepublicofcameroonfeasibilitytoleranceandeffectiveness
AT einterzem masstreatmentoftrachomawithazithromycin15eyedropsintherepublicofcameroonfeasibilitytoleranceandeffectiveness
AT goldschmidtp masstreatmentoftrachomawithazithromycin15eyedropsintherepublicofcameroonfeasibilitytoleranceandeffectiveness
AT bensaidp masstreatmentoftrachomawithazithromycin15eyedropsintherepublicofcameroonfeasibilitytoleranceandeffectiveness